Pharmidex
Peter H. is a highly experienced scientific advisor specializing in CNS drug delivery and biotechnology. Currently serving as a Member of the Scientific Advisory Board at Pharmidex since 2006, Peter H. also holds a position on the Biotechnology Industrial Advisory Board at Northeastern University, contributing to the enhancement of educational effectiveness within the Department of Biotechnology. Past roles include participation on various advisory boards at Johns Hopkins University and involvement in multiple scientific committees and editorial boards related to drug delivery and technology development. Formerly, Peter H. was Vice President of New Technology Development and Assessment at Genzyme, where extensive expertise shaped the strategic direction and success of product lines. Educational credentials include a PhD in Biochemistry from the University of Bonn and a postdoctoral degree from Johns Hopkins University.
This person is not in any teams
This person is not in any offices
Pharmidex
Pharmidex is an AAALAC-accredited, UK-based CRO founded in 2002. We provide high-quality, cost-effective, flexible and rapid solutions in drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP/GLP/GCP), toxicology (non-GLP/GLP), histology, clinical chemistry, hematology, and in vitro ADME. Pharmidex also offers in silico modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune, and metabolic disease programs. We work with over 250 global clients, including medical charities, academic groups, biotech, and pharma, and have undertaken over 15,000 studies. In addition to our fee-for-service offering, Pharmidex actively seeks collaboration opportunities in grant-funded projects. To date, we have successfully participated in over 30 collaborative grant-funded projects, partnering with more than 167 global collaborators.